Company Profile

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. It is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.

Employees

Sector

Biotechnology & Medical Research

More about the company

22-12-06	Zosano Pharma Corporation Went Out of Business	CI
22-11-22	Second Amended Liquidation Plan Approved for Zosano Pharma Corporation	CI
22-11-21	Second Amended Liquidation Plan Filed by Zosano Pharma Corporation	CI
22-11-17	First Amended Liquidation Plan Filed by Zosano Pharma Corporation	CI
22-10-10	First Amended Disclosure Statement Filed by Zosano Pharma Corporation	CI
22-10-07	Disclosure Statement Approved for Zosano Pharma Corporation	CI
22-09-21	First Motion for Exclusivity Period Extension Filed by Zosano Pharma Corporation	CI
22-08-25	Liquidation Plan and Disclosure Statement Filed by Zosano Pharma Corporation	CI
22-08-24	Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.	CI
22-08-08	Motion for Asset Sale Approved for Zosano Pharma Corporation	CI
22-07-25	Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.	CI
22-07-01	Bidding Procedure Approved for Zosano Pharma Corporation	CI
22-06-22	Motion for Case Conversion Filed for Zosano Pharma Corporation	CI

22-05-02	Maxim Downgrades Zosano Pharma to Hold From Buy	MT
22-02-23	BTIG Downgrades Zosano Pharma to Neutral From Buy	MT
20-11-25	Zosano Pharma : HC Wainwright Adjusts Zosano Pharma's Price Target to $2 From $2.50, Keeps at Buy	MT

22-06-03	ZOSANO PHARMA CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
22-06-02	Zosano Pharma : Files Voluntary Petition for Relief Under Chapter 11 - Form 8-K	PU
22-06-02	ZOSANO PHARMA CORP : Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22-06-02	Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11	AQ
22-05-18	ZOSANO PHARMA CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ

22-05-16	MÄRKTE USA/Zurückhaltung dominiert an der Wall Street
22-05-16	MÄRKTE USA/Wall Street neigt schon wieder zur Schwäche
22-05-16	MÄRKTE USA/Wall Street dürfte schon wieder zur Schwäche neigen

Manager	Title	Age	Since
Lu Liu CTO	Chief Tech/Sci/R&D Officer	-	2019-01-31
Mahmoud Ameri CTO	Chief Tech/Sci/R&D Officer	-	2014-12-31

Zosano Pharma Corporation Stock

Stocks

ZSAN

US98979H3012

Biotechnology & Medical Research

Latest news: Zosano Pharma Corporation

Analysts' recommendations: Zosano Pharma Corporation

Press Releases: Zosano Pharma Corporation

News in other languages: Zosano Pharma Corporation

Managers and Directors: Zosano Pharma Corporation

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/6/22	Christine Matthews	Sell	Chief Financial Officer	82	0.0017%
6/6/22	Steven Lo	Sell	Chief Executive Officer	442	0.0090%
3/31/22	Donald J. Kellerman	Sell	Chief Technology Officer	4,006	0.0023%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ZOSANO PHARMA CORPORATION	-.--%	-.--%	-	-	980
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.61%	+0.81%	+27.25%	+82.72%	60.14B
LONZA GROUP AG	-2.54%	-1.65%	+4.86%	+31.72%	48.15B
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	44.25B
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	43.99B
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	41.61B
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+8.00%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	24.93B
Average	-0.04%	-0.08%	+54.00%	+154.28%	44.09B
Weighted average by Cap.	+0.17%	+0.11%	+58.36%	+145.78%